Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metoprolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | NPY1R | P25929 | 1/20 | 1.00 |
| ▸ | NPY2R | P49146 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.84 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.84 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.84 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.84 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metoprolol SCHEMBL19211129 | 1.00 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL29995613 | 1.00 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL29367290 | 1.00 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL4881939 | 1.00 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL41104 | 1.00 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| (S)-Metoprolol SCHEMBL141366 | 1.00 | TDP1 (1.00) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL2124595 | 0.99 | TDP1 (0.98) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL4879331 | 0.98 | TDP1 (0.96) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| Metoprolol SCHEMBL28264735 | 0.97 | TDP1 (0.94) | TDP1PMP22NPY1RNPY2RNPSR1 | |
| (S)-Metoprolol SCHEMBL3123844 | 0.93 | ADRB2 (0.88) | TDP1PMP22NPY1RNPY2RNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118379516-A | Large-scale measurement point cloud efficient simplifying method based on improved feature descriptors | 大连理工大学 | 2024-07-23 | — | — | CN | claimed |
| CN-118141824-B | Application of alisol B acetate in preventing or treating hypertrophic cardiomyopathy | JIANGNAN UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| CN-114015692-B | Complement component C5 iRNA compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-118379516-A | Large-scale measurement point cloud efficient simplifying method based on improved feature descriptors | 大连理工大学 | 2024-07-23 | — | — | CN | disclosed |
| CN-118141824-A | Application of alisol B acetate in preventing or treating hypertrophic cardiomyopathy | 江南大学 | 2024-06-07 | — | — | CN | disclosed |
| US-20230218874-A1 | SWAB DELIVERY SYSTEM | ANERGENT PHARMACEUTICALS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-11623075-B2 | Buccal swab delivery system | ANERGENT PHARMACEUTICALS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-11607392-B2 | Encapsulation system for prolonged release of active agents | TREND INNOVATIONS (CA) | 2023-03-21 | — | — | US | disclosed |
| CN-114441663-A | Method for screening protein positive compounds by using solid phase microextraction affinity selection mass spectrum | 中国科学院上海药物研究所 | 2022-05-06 | — | — | CN | disclosed |
| EP-2211846-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | Pharnext (FR) | 2010-08-04 | — | — | EP | disclosed |
| WO-2010028211-A1 | HEALTH CARE | ROZMANITH ANTHONY I (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009068668-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2009-06-04 | — | — | WO | disclosed |
| EP-1303306-B1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND BETA-ADRENERGIC ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORP (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050215537-A1 | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | PHARMACIA CORPORATION | 2005-09-29 | — | — | US | disclosed |
| EP-1239280-A2 | ElogDoct:A tool for lipophilicity determination in drug discovery basic and neutral compounds | Pfizer Products Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0460064-A4 | THERAPEUTIC AEROSOL FORMULATIONS | — | 1992-04-01 | — | — | EP | disclosed |
| EP-0460064-A1 | THERAPEUTIC AEROSOL FORMULATIONS | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-12-11 | — | — | EP | disclosed |
| WO-1990009781-A1 | THERAPEUTIC AEROSOL FORMULATIONS | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1990-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215537-A1 | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | ADRB1, ADRB2, ADRB3 | ADRB1 1/4885TDP1 4874/4885PMP22 2074/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | ADRB1 746/4885TDP1 3124/4885PMP22 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.